Latest Rights Issue News

European Resources Limited (ASX: ERE) has announced a $4.26 million renounceable entitlement offer to accelerate exploration and metallurgical work at its Korsnäs rare earth elements project in Finland. The offer is partially underwritten and includes attaching options, providing shareholders with a strategic opportunity amid significant recent resource growth.

Regener8 Resources has announced a $2.03 million entitlement offer at a 41% discount, aiming to accelerate exploration and acquisition of its Srebrenica North Project. Eligible shareholders can subscribe at one new share for every two held, positioning the company for its next growth phase.

Evolution Energy Minerals has successfully closed an oversubscribed $4 million rights issue, supplemented by a $150,000 follow-on placement, bolstering funds for key exploration and development projects.

Identitii Limited has closed its recent rights issue, raising $379,336 before costs but falling short by $2.5 million after the termination of its underwriting agreement. The company plans to issue new shares and place the remaining shortfall to fund growth initiatives for its BNDRY platform.

Identitii Limited’s ID8N securities have been reinstated to trading following the close of its recent rights issue and the resolution of a Takeovers Panel application.

Magnetite Mines Limited has announced a renounceable rights issue aiming to raise up to $3.92 million to fund exploration across its South Australian tenements and advance the Razorback Iron Ore Project, recently awarded Major Project Status.

Eden Innovations Ltd reports a $1.43 million half-year profit, reversing prior losses thanks to a $4.45 million property sale and significant debt reduction, while advancing international commercialisation of its concrete and fuel technologies.

Halo Technologies Holdings Ltd posted a $17.4 million loss for 2025, widening from $14.5 million the previous year, as revenue fell 16%. The company completed a $3.9 million rights issue and announced a strategic pivot in its UK operations.

Activeport Group Ltd reported a 36% revenue decline and a 25% increase in net loss for the half-year ended December 2025, while securing key contracts with Tier 1 telcos and raising $8.8 million in capital.

Aland Equity Group reported a sharp revenue decline and an 85% increase in losses for the half-year ending December 2025, while completing a major capital raise and reshuffling its board.

Biotron Limited reported a half-year loss as it completed the acquisition of Sedarex Limited and advanced its Hepatitis B drug candidate BIT-HBV001, backed by a $2.5 million capital raise. The company faces material uncertainty over its going concern status, hinging on securing further funding.

Percheron Therapeutics reports a 64% reduction in half-year losses to $3.1 million, driven by progress in its licensed immuno-oncology drug HMBD-002 and a strategic pivot away from discontinued assets.